Sweden Pharmaceuticals & Healthcare Report Q2 2013
Published by Business Monitor International
on Mar 7, 2013
, 98 pages
PDF - Download Now with 3 Quarterly Updates format - Delivered by download
BMI View: We remain of the opinion that the value of the Swedish pharmaceutical market will decline in US dollars over our five-year forecast period to 2017, partly on account of deteriorating external economic environment, with stagnation on the cards in local currency terms. While the latter will nudge into a positive territory over the ten-year forecast period, US growth rates will remain negative, thus discouraging multinational involvement, especially given that patented medicines will continue to be squeezed by factors such as patent expirations and cost-containment strategies.